The global nucleic acid labeling market, valued at $1.7 billion in 2025, is projected to grow to $2.8 billion by 2032 at a 7% CAGR. Growth is fueled by advances in genomics, molecular diagnostics, and personalized medicine, with increasing demand for automated, high-throughput labeling technologies. Key applications include gene expression analysis and disease biomarker detection, supported by strong investments in cancer research and genetic testing. The U.S. and China are major markets, with significant growth expected in Asia-Pacific and Europe.
Merck & Co. and Agilent Technologies are key players in the nucleic acid labeling market. As of Nov 10, 2026 22:12 WIB, Merck trades at USD 146.99, down 1.16%, with a market cap of $366.73B on Pluang. Agilent is priced at USD 177.84, down 1.29%, with a market cap of $50.80B. Investor activity on Pluang shows 89% selling for Merck, reflecting cautious sentiment amid market shifts.
Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...
Halozyme Therapeutics reported a 39% year-over-year revenue increase to $493 million in Q3 2026, driven by a 44% rise in royalty revenue to $341 million. The company expanded its ENHANZE® collaboration agreements and advanced three programs into Phas...
